Gemina Laboratories Ltd. (TSE:GLAB) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gemina Laboratories Ltd. has enhanced its intellectual property portfolio by licensing a new biosensing technology from the University of British Columbia, which promises to advance point-of-care diagnostics with high-sensitivity and affordability. The novel biosensing architecture will contribute to the development of diagnostic tests, including a test kit targeting tuberculosis that aligns with the global health initiative to end TB by 2030. This strategic move aligns with Gemina’s ongoing efforts to broaden the application of its core technology platform in point-of-care diagnostics.
For further insights into TSE:GLAB stock, check out TipRanks’ Stock Analysis page.